The Latest Breaking News from TMO

Thermo Fisher Scientific has lagged behind the Dow Jones Industrial over the past year, but analysts maintain a strong bullish outlook on its future performance.

Could Thermo Fisher Scientific Inc. (NYSE:TMO) be the unsung hero of the biopharma sector's future? While its stock performance has recently lagged, analysts are betting on a major turnaround driven by strategic acquisitions and robust growth potential. William Blair initiated coverage on Tuesday on Thermo Fisher Scientific, citing a strong…

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

While Thermo Fisher Scientific has underperformed the broader market over the past year, Wall Street analysts continue to hold a bullish view of the stock’s long-term prospects.

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23.

When a toenail in touch by a defending team results in a try being chalked off for those on the attack, the game is making itself look idiotic

Thermo Fisher Scientific is poised to release its second-quarter results later this month, and analysts project a single-digit earnings drop.

While Quest Diagnostics has outshined the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Even though Waters Corporation has outshined the industry peers over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

While TMO stock has represented one of the biggest market losers, a sentiment reversal could be in the works.

Thermo Fisher Scientific has notably underperformed the Nasdaq Composite over the past year, yet analysts remain bullish about the stock’s prospects.